Catalog No.:AA0037MI

5291-32-7 | APR-246

Name: Name:APR-246
Brand: AABLOCKS
SKU: AA0037MI
Availability: InStock
Rating: 90 (10 reviews)

Pack Size

Purity

Availability

Price(USD)

Quantity

1mg

97%

in stock

$14.00 $10.00

- +

5mg

97%

in stock

$46.00 $32.00

- +

10mg

97%

in stock

$68.00 $48.00

- +

25mg

97%

in stock

$114.00 $80.00

- +

50mg

97%

in stock

$185.00 $130.00

- +

100mg

97%

in stock

$310.00 $217.00

- +

250mg

95%

in stock

$522.00 $365.00

- +

Technical Information
Properties
Downstream Synthesis Route
Literature
Request for Quotation
Download SDS

Technical Information
Properties
Downstream Synthesis Route
Literature

Technical Information

Catalog Number:

AA0037MI

Chemical Name:

APR-246

CAS Number:

5291-32-7

Molecular Formula:

C10H17NO3

Molecular Weight:

199.2469

MDL Number:

MFCD20620963

SMILES:

COCC1(CO)N2CCC(C1=O)CC2

Properties

Form:

Solid

MP:

>105°C (dec.)

Storage:

Keep in dry area;2-8℃;

Computed Properties

Complexity:

236

Covalently-Bonded Unit Count:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Rotatable Bond Count:

Undefined Atom Stereocenter Count:

XLogP3:

-0.1

Downstream Synthesis Route

5291-32-7

13734-41-3

(2-(methoxymethyl)-3-oxoquinuclidin-2-yl)methyl(tert-butoxycarbonyl)-L-valinate

[1]CurrentPatentAssignee:NEWAVEPHARMACEUTICALINC-WO2021/158948,2021,A1Locationinpatent:Page/Pagecolumn83

5291-32-7

13734-41-3

(2-(methoxymethyl)-3-oxoquinuclidin-2-yl)methylL-valinatehydrochloride

[1]CurrentPatentAssignee:NEWAVEPHARMACEUTICALINC-WO2021/158948,2021,A1

5291-32-7

2-(methoxymethyl)-3-oxo-1-azabicyclo2.2.2octan-2-ylmethyl(2S)-2-amino-3-methylbutanoate

530-62-1

2-(methoxymethyl)-3-oxo-1-azabicyclo2.2.2octan-2-ylmethyl(2S)-2-(2-(methoxymethyl)-3-oxo-1-azabicyclo2.2.2octan-2-ylmethoxycarbonyl)amino-3-methylbutanoate

[1]CurrentPatentAssignee:NEWAVEPHARMACEUTICALINC-WO2021/158948,2021,A1Locationinpatent:Page/Pagecolumn83-84

5291-32-7

100-21-0

bis((2-(methoxymethyl)-3-oxoquinuclidin-2-yl)methyl)terephthalate

[1]CurrentPatentAssignee:NEWAVEPHARMACEUTICALINC-WO2021/158948,2021,A1Locationinpatent:Page/Pagecolumn84-85

Literature

Title: Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress.

Journal: Cancers 20180401

Title: p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.

Journal: European journal of cancer (Oxford, England : 1990) 20160301

Title: PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110501

Title: Pharmacological rescue of p53 in cancer cells: the soloist meets the PRIMA donna.

Journal: Cell cycle (Georgetown, Tex.) 20110315

Title: Unleash the wild type: restoration of p53 suppressive activity in skin cancer.

Journal: Cell cycle (Georgetown, Tex.) 20110301

Title: PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.

Journal: Cell cycle (Georgetown, Tex.) 20110115

Title: p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma.

Journal: Oral oncology 20110101

Title: Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis.

Journal: Oncogene 20100304

Title: PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein.

Journal: Molecular cancer 20090101

Title: PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2.

Journal: Oncogene 20081120

Title: Peng X, et al. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881.

Title: Stuber G, et al. PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein. Mol Cancer. 2009 Mar 26;8:23.

Title: Sallman DA, et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021;39(14):1584-1594.

Quotation Request

Company Name:

Contact Person:

Email:

Quantity Required:

Country:

Additional Info:

SDS